201 results about "Autologous cell" patented technology

Materials and methods for treating tissue defects in human or animal tissues using implantable cells are described. Further, culture techniques and factors for enhancing these procedures, and cell survival and adaptation are described. Many of the tissue defects may be treated with autologous cells, while applications involving non-autologous cells or stem cells are also described.

Compositions and methods of treating a defect in a patient are disclosed, including expanding a culture of autologous cells in vitro to form cultured cells, collecting the cultured cells for introduction into the patient, and depositing the cultured cells with ancillary proteins.

The present invention relates to utrons, RNA molecules which contain promoter regulatory motif(s) and DNA analogs thereof and DNA molecules that can be transcribed to produce the foregoing. In particular, the invention provides gene promoter suppressing nucleic acids which suppress transcription from a promoter of interest. In a preferred embodiment, the invention provides the TSU gene, nucleotide sequences of the TSU gene and RNA, as well as fragments, homologs and derivatives thereof. Methods of isolating TSU genes are also provided. Therapeutic and diagnostic methods and pharmaceutical compositions are also provided. In particular, the invention relates to methods for cell replacement therapy, gene therapy or organ transplantation wherein TSU nucleic acids suppress MHC class I and II gene expression, thus preventing immuno-rejection of non-autologous cells or organs. The invention also provides methods for treatment of diseases or disorders by suppression of MHC class I, MHC class II, ICAM-1, B7-1, B7-2, and/or Fc gamma R expression by provision of TSU function.

A method of carrying out an autologous tissue implant in a subject in need thereof is carried out by: (a) forming an autologous tissue implant from autologous cells collected from a subject (e.g., by ink-jet printing, the autologous cells and the scaffold, separately or together), and then (b) implanting the autologous tissue implant in said subject.

The present invention relates to the regeneration, reconstruction, repair, augmentation or replacement of organs or tissue structures using scaffolds and autologous cells that are not derived from such organs or tissues.

The present application describes various applications of the non-expansion protocol for the preparation of an injectable autologous cell mixture of the present invention that can be used to prevent symptoms in a number of indications. Cells are isolated from surgically derived tissue and are at least partially disaggregated from each other. The heterologous cell mixture is mixed with growth factors, differentiation agents, extracellular matrix proteins and/or microspheres and injected into the patient without cell expansion. The harvesting of tissue, cell isolation, and injection are performed within a single surgical procedure lasting only minutes to hours.

The invention provides artificial articular cartilage based on autologous cells and a preparation method thereof. The artificial articular cartilage comprises a nano bionic support and hydrosol adhered to the nano bionic support, wherein one or more cytokines are coated into the hydrosol. The invention also provides the method for preparing the artificial articular cartilage, which comprises the following steps: preparing an electrostatic spinning solution, a cytokine-containing hydrosol solution and a crosslinking agent solution; using the crosslinking agent solution to receive electrostatic spinning so as to prepare the nano bionic support; and using an ink jet printer to print the cytokine-containing hydrosol solution on the nano bionic support, and curing the hydrosol to obtain the artificial articular cartilage. The three-dimensional support adopted by the invention has ideal degradation speed and is degraded after the regeneration of an articular cartilage layer, can meet the requirement of actual clinical application, can be completely degraded, and has good abrasion resistance and lubricity so as to be capable of replacing the cartilage before the regeneration of the articular cartilage layer.

The present invention relates to administering autologous uncultured cells into a diseased intervertebral disc.

The present invention relates to a pharmaceutical composition for promoting arteriogenesis, and preparation method and applications of the same, wherein said pharmaceutical composition comprises an effective amount of a drug, and a peptide hydrogel, and it forms a microenvironment for autologous cell recruitment and tissue regeneration.

The invention relates to a culture medium efficiently amplifying autologous NK cells and a culture method. The culture medium internally contains interleukin 2(IL-2), interleukin 15(IL-15), interleukin 7(IL-7), interleukin 12(IL-12), tumor necrosis factor alpha (TNFalpha) and CD3-antibody, can efficiently amplify and activate NK cells so as to obtain a large quantity of highly active immune cells with majority of NK cells to be transferred back to human bodies, and has remarkable curative effect in anti-tumor, anti-virus infection and immune adjustment related diseases. The culture medium efficiently amplifying autologous NK cells comprises the culture medium for cultivating cells and added factors added into the culture medium for cultivating cells, is used for cultivating and amplifying a large quantity of autologous activated NK cells, and is characterized in that the added factor comprises interleukin 2(IL-2), interleukin 15(IL-15), interleukin 7(IL-7), interleukin 12(IL-12), tumor necrosis factor alpha (TNF alpha) and CD3-antibody.

An endoscopic method for treating cartilage or bone defects in an animal, said method comprising the steps of: I) identifying the position of the defect, ii) applying cells selected from the group consisting of chondrocytes, chondroblasts, osteocytes and osteoblasts and combinations thereof into the cartilage or bone defect. In particular, the invention relates to a method for arthroscopic or endoscopic implantation of homologous or autologous cells into a defect of an animal body, the method comprising a step of I) arthroscopic or endoscopic application of a fluid to a cavity or surface containing the defect, and the steps of ii) application of the cells to the defect substantially simultaneously with a support material, the application being performed at the defect covered by the fluid, iii) mixing of the cells and the supporting material, iv) solidification of the supporting material so that the defect is covered by a mixture of cells and support material without any significant amount of fluid, and v) optionally, removal of the fluid from the cavity or surface by drainage or suction.

The invention relates to an optimal method for efficiently separating and expanding mesenchymal stem cells in umbilical cord blood in cell therapy. The fact that the mesenchymal stem cells with higher differentiative capacity and smaller immunological rejection are contained in the umbilical cord blood has been proved. The establishment of an umbilical cord blood bank provides a basis for achieving transplantation of autologous cells. However, since the content of the mesenchymal stem cells in the umbilical cord blood is very low (only 0.5 to 30 mesenchymal stem cells are contained in 1*108 mononuclear cells), how to efficiently separate and expand the mesenchymal stem cells becomes a problem hindering the transformation of the mesenchymal stem cells in the umbilical cord blood to the clinical application. At present, in most situations, the mesenchymal stem cells in the umbilical cord blood are separated in virtue of adsorption capacity of the mesenchymal stem cells in a culture vessel, but the success ratio is low, and the characteristics of stem cells are difficult to maintain in an expanding process. The method comprises the steps of coating the culture vessel with protein components, adding multiple growth factors in the culture vessel in a coordination manner, and building the expansion environment of the mesenchymal stem cells in the umbilical cord blood, so as to achieve the efficient separation and expansion of the mesenchymal stem cells.

Disclosed is a therapeutic autologous-cell delivery support system 100, in which a therapeutic autologous cell extracted from a member is reserved in reserve means 34, and an autologous-cell delivery request from the member which includes ID information and positional information is received. Membership information is retrieved in accordance with the received ID information, and the membership information and positional information of the member is output. When the reserve means is provided in plural number at geographically different locations, one reserve means having a shortest delivery time is selected in accordance with the positional information included in the delivery request. The delivery request can be issued using ID information storage means 11 for transmitting the ID information, in a simple operation, or automatically issued using a monitor of physical data.

A method for expanding mesenchymal cells derived from autologous bone marrow in autologous culture medium which can be used in a clinical setting, and a business method for performing such expansions in the future as a service for patients. A method for expanding mesenchymal cells derived from autologous bone marrow in autologous culture medium including a diagnostic kit for the autologous cell therapy to determine whether a patient will respond to the autologous cell therapy for treatment of a disease, in which said kit comprising a system for detecting gene and protein expression comprising at least two isolated DNA molecules wherein each isolated DNA molecule detects expression of a gene that is differentially expressed in the tissue of the patient that is intended to be the source of the autologous cell therapy.

The invention relates to a method of making pluripotent stem cells that does not involve the formation of early preimplantation embryos or fetal tissue. The method has general utility in the production of pluripotent stem cells from many mammalian species but has particular application in man where pluripotent stem cell production can be customized to particular human individual. The method involves the fusion of donor somatic or stem cells (or their karyoplasts) with cytoplasmic, membrane-delimited fragments of mammalian oocytes or zygotes. After the initial genomic reprogramming occurs, the cells can proliferate and thus multiply in vitro yielding a large number of autologous cells for cell therapy application. The result of this process is a cell population genomically identical to the somatic, differentiated cells derived from an individual patient. However, these cells are pluripotent in that upon application of specific growth factors, the cells are capable of differentiating into specific cell types as required by the sought clinical indication.

Disclosed herein are embodiments of long-term ambulatory intra-aortic balloon pump systems for providing left ventricular cardiac assistance to a patient. The systems can comprise an external drive system for supplying a compressed fluid, the drive system operating in accordance with a control program stored in memory, an intra-luminal balloon pump having an elongate inflatable chamber positionable to be lying completely within a descending aorta of the patient, and a percutaneous access device. The percutaneous access device can be a biocompatible implantable portal comprising a communicative passage through an interior bore and an exterior having a neck region adapted to promote autologous cell growth thereon in an implantable region, the neck region having a plurality of channels extending about the neck region.

A biocompatible implantable portal is provided that has a wall defining a communicative passage through an interior bore. The exterior of the portal has a neck region adapted to promote autologous cell growth on the neck region. A series of channels are provided on the exterior neck region to facilitate autologous cell growth while disfavoring fluid pooling and bacterial growth. Typical channel widths are from 20 to 300 microns, with adjacent channels being separated by plateaus having a width of between 0 and 600 microns. Providing the portal exterior neck region with a texture varying on a nanometer length scale facilitates autologous cell growth. Applying a coating such as a tissue scaffolding matrix to the neck region prior to implantation also facilitates cell growth. A coupling or a manifold encompassing the neck region facilitates the draw of vacuum and/or mechanical protection for the growing cells.